Clinical Research Directory

Inclusion Criteria: * cancer patients ages ≥18 years * have received a medication in one of the following categories: platinum-based, vinca alkaloids, bortezomib, eribulin, and/or taxanes * have CIN due to receiving neurotoxic chemotherapy for cancer or have pre-existing peripheral neuropathy of another etiology that worsened after chemotherapy * have one of the average intensity of pain, or numbness, or tingling on their extremities the previous week due to CIN ≥ 4 on a 11-point numerical scale. Exclusion Criteria: * use of an investigational agent for pain control concurrently or within the past 30 days * use of an implantable drug delivery system, e.g. Medtronic SynchroMed® * prior celiac plexus block or other neurolytic pain control treatment * other identified causes of painful paresthesia existing prior to chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy,) * allergy to latex (the tapes for the APA include latex) and/or having a history of allergic reactions to the adhesive tape * pregnant women (based on the self-reported data) * individuals diagnosed with diabetic neuropathy